Clinical trial · Interventional
Impact of the Distribution to Attending Physicians of a Nominative List of Their Patients Not Participating in the Organised Screening of Colorectal Cancer
Impact of the Distribution to Attending Physicians of a Nominative List of Their Patients Not Participating in the Organised Screening of Colorectal Cancer: Randomised Study Measuring the Impact on Participation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Objective : to demonstrate that providing to GPs a list of their patients who are not compliant to colorectal cancer screening will 1) enhance patient participation to screening, and 2) decrease the proportion of cancer diagnosed outside the screening organisation. Design : Randomised controlled study, 3 parallel arms. Enrollment: GPs allocated in the 3 groups of the study will be all GPs 1) from the "Loire-Atlantique and Vendée" geographic area (1300 GPs on average) and 2) who have more than 100 patients in their patient list (based on data provided by the Healthcare Insurance System Services). Patients will be eligible to the study depending on their eligibility to the Faecal Occult Blood Test for colorectal cancer screening : 1) they should be older than 50 and younger than 74; 2) they should not have a personal history of colorectal cancer (or history of adenoma bigger than 1 cm) nor a family history of colorectal cancer. Main outcomes measures : Patient participation to colorectal cancer screening, and number of cancers screened in (versus diagnosed outside) the screening procedure.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Providing a list of patients not compliant with CRC sreening | Other | — | UNRESOLVED |
| Providing general information about CRC sreening | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- A: nominative list
- description
- Providing a list of patients not compliant with CRC sreening General Practitioners allocated to the intervention group (A) will receive: * a nominative list of their patients who were not compliant to colorectal cancer screening. * a document providing general information about colorectal cancer screening
- interventionNames
- Other: Providing a list of patients not compliant with CRC sreening
- Other: Providing general information about CRC sreening
- type
- ACTIVE_COMPARATOR
- label
- B: general information
- description
- Providing general information about CRC screening General Practitioners allocated to group (B) will receive: \- a document providing general information about colorectal cancer screening (but will not receive the nominative list of patients non compliant to colorectal cancer screening)
- interventionNames
- Other: Providing general information about CRC sreening
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 25 Years
- Maximum age
- 74 Years
Show eligibility criteria text
In this study, the statistical unit is the GP. Inclusion Criteria: GPs allocated in the 3 groups of the study will be all GPs * 1\) from the "Loire-Atlantique and Vendée" geographic area (1300 GPs on average) * 2\) who have more than 100 patients in their patient list (based on data provided by the Healthcare Insurance System Services). Exclusion Criteria: * GPs who have less than 100 patients in their patient list
References
Publications (1)
- DERIVEDRat C, Pogu C, Le Donne D, Latour C, Bianco G, Nanin F, Cowppli-Bony A, Gaultier A, Nguyen JM. Effect of Physician Notification Regarding Nonadherence to Colorectal Cancer Screening on Patient Participation in Fecal Immunochemical Test Cancer Screening: A Randomized Clinical Trial. JAMA. 2017 Sep 5;318(9):816-824. doi: 10.1001/jama.2017.11387. PMID 28873160